

1S A Bright Future for Nuclear Endocrinology

David Taïeb, Elif Hindié, and David Mankoff

Taïeb and colleagues introduce this special *JNM* supplement and preview the topics and issues addressed by experts in the field.

3S Primary Hyperparathyroidism: Defining the Appropriate Preoperative Imaging Algorithm

Elif Hindié, Paul Schwartz, Anca M. Avram, Alessio Imperiale, Frederic Sebag, and David Taïeb

Hindié and colleagues discuss the aims of preoperative imaging in this setting and suggest an imaging algorithm for use before first surgery or before repeat surgery for persistent or recurrent disease.

13S Update on the Evaluation of Thyroid Nodules

Victor J. Bernet and Ana-Maria Chindris

Bernet and Chindris provide an update on current research and experience in the epidemiology, diagnosis, and management of thyroid nodules, with consensus recommendations from the literature.

20S Molecular Imaging for Thyrotoxicosis and Thyroid Nodules

Luca Giovannella, Anca Avram, and Jerome Clerc

Giovannella and colleagues summarize basic concepts, clinical applications, and potential developments in thyroid molecular imaging for patients affected by thyrotoxicosis and thyroid nodules.

26S A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses

Anders Sundin, Elif Hindié, Anca M. Avram, Antoine Tabarin, Karel Pacak, and David Taïeb

Sundin and colleagues review well-established and emerging nuclear medicine imaging modalities for evaluation of adrenal masses and describe their use across a range of clinical scenarios.

34S Perspectives on Brown Adipose Tissue Imaging: Insights from Preclinical and Clinical Observations from the Last and Current Century

John P. Crandall and Richard L. Wahl

Crandall and Wahl highlight key aspects of brown adipose tissue biology, pitfalls in image interpretation, methods to intentionally reduce BAT uptake, and multiple imaging methods used to identify BAT in vivo.

44S Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?

Damian Wild, Kwadwo Antwi, Melpomeni Fani, and Emanuel R. Christ

Wild and colleagues present an overview of current preclinical and clinical evaluation of radiolabeled glucagon-like peptide-1 analogs for SPECT/CT and PET/CT imaging, as well as their clinical potential.

51S ¹⁸F-6-Fluoro-L-Dopa PET/CT Imaging of Congenital Hyperinsulinism

Lisa J. States, J. Christopher Davis, Steven M. Hamel, Susan A. Becker, and Hongming Zhuang

States and colleagues survey the role of ¹⁸F-6-fluoro-L-dopa PET/CT in the management of infants and children in this challenging clinical presentation.

57S Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas

Wael A. Bashari, Russell Senanayake, James MacFarlane, Daniel Gillett, Andrew S. Powlson, Angelos Koliass, Richard J. Mannion, Olympia Koulouri, and Mark Gurnell

Bashari and colleagues summarize published evidence supporting the use of molecular imaging in the management of pituitary adenomas, including their collective 10-year experience with ¹¹C-methionine PET.

GUEST EDITORS

David Taïeb, MD
La Timone University Hospital,
CERIMED, Aix-Marseille University
Marseille, France

Elif Hindié, MD, PhD
Bordeaux University Hospitals,
University of Bordeaux
Bordeaux, France

David A. Mankoff, MD, PhD
University of Pennsylvania
Philadelphia, Pennsylvania

Editor-in-Chief
Johannes Czernin, MD
David Geffen School of Medicine at UCLA
Los Angeles, California

Opinions expressed in the contributions to this supplement are solely those of the authors and do not necessarily reflect those of *The Journal of Nuclear Medicine* or the Society of Nuclear Medicine and Molecular Imaging. The journal, however, invites and welcomes different opinions in order to initiate and stimulate discussion.